The FDA's announcement on February 21, 2025, declared the Semaglutide shortage resolved, triggering new restrictions on compounding (FDA Clarifies Policies for Compounders)
This includes lifestyle guidance, progress monitoring, and ongoing provider support to promote sustainable results and long-term weight management
Analyzing a 2025 survey of U.S
CVD Safety Semaglutide has a well-established FDA approval for reducing the risk of major adverse cardiovascular events (MACE) in high-risk patients, based on the SELECT trial which demonstrated a 20% reduction in MACE over a mean 39.8-month follow-up
GLP-1 users arent causing a seismic shift in restaurant behavior changes are more gradual and took a couple of years to come about, said Brooks Berrodin, director of Thought Leadership, Foodservice at Circana While it is important for restaurants to adjust to the changing reality, GLP-1s arent yet disrupting the industry. One of the most noticeable shifts is in portion sizes as consumers are no longer looking to super size their orders and instead they are looking for ways to manage the amount they eat and drink, Berrodin explained
Monitor the timing of your hair loss